ヘパリンの世界市場2021年-2028年:製品別(未分画ヘパリン、低分子量ヘパリン(LMWH)、超低分子量ヘパリン(ULMWH))、用途別、流通チャネル別

◆英語タイトル:Heparin Market by Product (Unfractionated Heparin, Low Molecular Weight Heparin (LMWH), and Ultra-Low Molecular Weight Heparin (ULMWH)), Application (Venous Thromboembolism, Coronary Artery Disease, Atrial Fibrillation, and Others), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021–2028
◆商品コード:AMR21JU030
◆発行会社(リサーチ会社):Allied Market Research
◆発行日:2021年5月21日
◆ページ数:221
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD6,168 ⇒換算¥678,480見積依頼/購入/質問フォーム
5 UserUSD6,929 ⇒換算¥762,190見積依頼/購入/質問フォーム
Enterprise UserUSD9,663 ⇒換算¥1,062,930見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はAllied Market Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Allied Market Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本調査資料では、ヘパリンの世界市場について調査し、イントロダクション、エグゼクティブサマリー、市場状況、製品別(未分画ヘパリン、低分子量ヘパリン(LMWH)、超低分子量ヘパリン(ULMWH))分析、用途別(静脈血栓塞栓症、冠状動脈疾患、心房細動、その他)分析、流通チャネル別(病院薬局、ドラッグストア・小売薬局、オンライン薬局)分析、地域別分析、企業情報などを掲載しています。
・イントロダクション
・エグゼクティブサマリー
・市場状況
・ヘパリンの世界市場規模:製品別(未分画ヘパリン、低分子量ヘパリン(LMWH)、超低分子量ヘパリン(ULMWH))
・ヘパリンの世界市場規模:用途別(静脈血栓塞栓症、冠状動脈疾患、心房細動、その他)
・ヘパリンの世界市場規模:流通チャネル別(病院薬局、ドラッグストア・小売薬局、オンライン薬局)
・ヘパリンの世界市場規模:地域別
・企業情報
【レポートの概要】

The global heparin market was valued at $6,535 million in 2020, and is projected to reach $11,015 million by 2028, registering a CAGR of 6.6% from 2021 to 2028.

Heparin is an anticoagulant medication and a naturally occurring glycosaminoglycan produced by basophils and mast cells in all mammals. It is used to prevent formation of blood clots caused by certain medical conditions or medical procedures. It is used in the treatment of various health conditions, such as acute coronary syndrome, deep-vein thrombosis, pulmonary embolism, atrial fibrillation, and is also used during heart surgery for carrying out cardiopulmonary bypass as well as hemofiltration. It is also administered for major orthopedic surgeries such as hip replacement and knee replacement. Recent development in heparin research to develop heparin with ultra-low molecular weight for utilization in chemotherapy opened new avenues for the heparin market.

Rise in occurrence of venous thrombosis due to various underlying factors, such as cardiovascular diseases, drive the growth of the global heparin market. In addition, application of heparin in various surgeries, such as orthopedic and heart surgeries, and increase in number of patients undergoing such surgeries further boost the growth of the market. However, many adverse side-effects associated with heparin, such as heparin-induced thrombocytopenia, restrain the growth of the market. In addition, as heparin is derived from animal sources, it poses a significant safety and supply issue, which further limits the growth of the market. In contrast, availability of synthetic and semi-synthetic heparin mimetics that assist in treating various cancers, coagulation, and inflammatory diseases is anticipated to provide lucrative opportunities for the adoption of heparin products. Moreover, increase in government funding toward improving healthcare facilities and extensive R&D activities to develop heparin with improved therapeutic potential and minimal side-effects are anticipated to further provide lucrative opportunities to the market.

The global heparin market is segmented into product, application, distribution channel, and region. On the basis of product, the market is categorized into unfractionated heparin, low molecular weight heparin (LMWH), and ultra-low molecular weight heparin (ULMWH). By application, it is classified into venous thromboembolism, atrial fibrillation, coronary artery disease, and others. By distribution channel, it is divided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the global heparin market along with the current trends and future estimations to explain the imminent investment pockets.
• A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
• Comprehensive quantitative analysis of the industry from 2020 to 2028 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
• Extensive analysis of the key segments of the industry helps to understand the application and products of heparin used across the globe.
• Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS
By Product
• Unfractionated Heparin
• Low Molecular Weight Heparin (LMWH)
• Ultra-low Molecular Weight Heparin (ULMWH)

By Application
• Venous Thromboembolism
• Coronary Artery Disease
• Atrial Fibrillation
• Others

By Distribution Channel
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies

By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA

LIST OF KEY PLAYERS PROFILED IN THE REPORT
• Baxter International Inc.
• B. Braun Holding GmbH & Co. KG
• Dr. Reddy’s Laboratories Ltd.
• Fresenius SE & Co KGaA
• Hebei Changshan Biochemical Pharmaceutical Co., Ltd.
• Leo Pharma A/S
• Pfizer Inc.
• Sanofi S.A
• Teva Pharmaceuticals
• Viatris Inc.

【レポートの目次】

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key Benefits for Stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets
3.2.2.Top winning strategies

3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5Market dynamics

3.5.1.Drivers

3.5.1.1.Increase in incidence of venous thromboembolism and cardiovascular disorders
3.5.1.2.Rise in geriatric population
3.5.1.3.Increase in usage of heparin in surgical procedures

3.5.2.Restraints

3.5.2.1.Side effects associated with heparin
3.5.2.2.Presence of alternative anticoagulants

3.5.3.Opportunities

3.5.3.1.Availability of synthetic and semi-synthetic heparin mimetics
3.5.3.2.R&D activities to develop heparin with improved therapeutic

3.5.4.Impact analysis

3.6Covid-19 Impact analysis on heparin market

CHAPTER 4:HEPARIN MARKET, BY PRODUCT

4.1.Overview

4.1.1.Market size and forecast

4.2.Unfractionated Heparin

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Low Molecular Weight Heparin (LMWH)

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

4.4.Ultra-low Molecular Weight Heparin (ULMWH)

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

CHAPTER 5:HEPARIN MARKET, BY APPLICATION

5.1.Overview

5.1.1.Market size and forecast

5.2.Venous Thromboembolism

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Coronary Artery Disease

5.3.1.Market size and forecast
5.3.2.Market analysis, by country

5.4.Atrial Fibrillation

5.4.1.Market size and forecast
5.4.2.Market analysis, by country

5.5.Others

5.5.1.Market size and forecast
5.5.2.Market analysis, by country

CHAPTER 6:HEPARIN MARKET, BY DISTRIBUTION CHANNEL

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospital Pharmacies

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Drug stores and retail pharmacies

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Online pharmacies

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:HEPARIN MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country

7.2.2.1.U.S.

7.2.2.1.1.U.S. heparin market, by product
7.2.2.1.2.U.S. heparin market, by application
7.2.2.1.3.U.S. heparin market, by distribution channel

7.2.2.2.Canada

7.2.2.2.1.Canada heparin market, by product
7.2.2.2.2.Canada heparin market, by application
7.2.2.2.3.Canada heparin market, by distribution channel

7.2.2.3.Mexico

7.2.2.3.1.Mexico heparin market, by product
7.2.2.3.2.Mexico heparin market, by application
7.2.2.3.3.Mexico heparin market, by distribution channel

7.2.3.North America market size and forecast, by product
7.2.4.North America market size and forecast, by application
7.2.5.North America market size and forecast, by distribution channel

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country

7.3.2.1.Germany

7.3.2.1.1.Germany heparin market, by product
7.3.2.1.2.Germany heparin market, by application
7.3.2.1.3.Germany heparin market, by distribution channel

7.3.2.2.France

7.3.2.2.1.France heparin market, by product
7.3.2.2.2.France heparin market, by application
7.3.2.2.3.France heparin market, by distribution channel

7.3.2.3.UK

7.3.2.3.1.UK heparin market, by product
7.3.2.3.2.UK heparin market, by application
7.3.2.3.3.UK heparin market, by distribution channel

7.3.2.4.Italy

7.3.2.4.1.Italy heparin market, by product
7.3.2.4.2.Italy heparin market, by application
7.3.2.4.3.Italy heparin market, by distribution channel

7.3.2.5.Spain

7.3.2.5.1.Spain heparin market, by product
7.3.2.5.2.Spain heparin market, by application
7.3.2.5.3.Spain heparin market, by distribution channel

7.3.2.6.Rest of Europe

7.3.2.6.1.Rest of Europe heparin market, by product
7.3.2.6.2.Rest of Europe heparin market, by application
7.3.2.6.3.Rest of Europe heparin market, by distribution channel

7.3.3.Europe market size and forecast, by product
7.3.4.Europe market size and forecast, by application
7.3.5.Europe market size and forecast, by distribution channel

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country

7.4.2.1.Japan

7.4.2.1.1.Japan heparin market, by product
7.4.2.1.2.Japan heparin market, by application
7.4.2.1.3.Japan heparin market, by distribution channel

7.4.2.2.China

7.4.2.2.1.China heparin market, by product
7.4.2.2.2.China heparin market, by application
7.4.2.2.3.China heparin market, by distribution channel

7.4.2.3.India

7.4.2.3.1.India heparin market, by product
7.4.2.3.2.India heparin market, by application
7.4.2.3.3.India heparin market, by distribution channel

7.4.2.4.Australia

7.4.2.4.1.Australia heparin market, by product
7.4.2.4.2.Australia heparin market, by application
7.4.2.4.3.Australia heparin market, by distribution channel

7.4.2.5.Rest of Asia-Pacific

7.4.2.5.1.Rest of Asia-Pacific heparin market, by product
7.4.2.5.2.Rest of Asia-Pacific heparin market, by application
7.4.2.5.3.Rest of Asia-Pacific heparin market, by distribution channel

7.4.3.Asia-Pacific market size and forecast, by product
7.4.4.Asia-Pacific market size and forecast, by application
7.4.5.Asia-Pacific market size and forecast, by distribution channel

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country

7.5.2.1.Brazil

7.5.2.1.1.Brazil heparin market, by product
7.5.2.1.2.Brazil heparin market, by application
7.5.2.1.3.Brazil heparin market, by distribution channel

7.5.2.2.South Africa

7.5.2.2.1.South Africa heparin market, by product
7.5.2.2.2.South Africa heparin market, by application
7.5.2.2.3.South Africa heparin market, by distribution channel

7.5.2.3.Saudi Arabia

7.5.2.3.1.Saudi Arabia heparin market, by product
7.5.2.3.2.Saudi Arabia heparin market, by application
7.5.2.3.3.Saudi Arabia heparin market, by distribution channel

7.5.2.4.Rest of LAMEA

7.5.2.4.1.Rest of LAMEA heparin market, by product
7.5.2.4.2.Rest of LAMEA heparin market, by application
7.5.2.4.3.Rest of LAMEA heparin market, by distribution channel
7.5.3.LAMEA market size and forecast, by product
7.5.4.LAMEA market size and forecast, by application
7.5.5.LAMEA market size and forecast, by distribution channel

CHAPTER 8:COMPANY PROFILES

8.1.Baxter International Inc.

8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segment
8.1.4.Product portfolio
8.1.5.Business performance

8.2.B. Braun Holding GmbH & Co. KG

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segment
8.2.4.Product portfolio
8.2.5.Business performance

8.3.Dr. Reddy’s Laboratories Ltd.

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segment
8.3.4.Product portfolio
8.3.5.Business performance

8.4.Fresenius SE & Co KGaA

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segment
8.4.4.Product portfolio
8.4.5.Business performance
8.4.6.Key strategic moves and developments

8.5.Hebei Changshan Biochemical Pharmaceutical Co., Ltd.

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segment
8.5.4.Product portfolio

8.6.Leo Pharma A/S

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance

8.7.Pfizer Inc.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance

8.8.Sanofi S.A.

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.Teva Pharmaceuticals

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Product portfolio
8.9.4.Business performance

8.10.Viatris Inc.

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Product portfolio
8.10.4.Operating business segments
8.10.5.Business performance
8.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.HEPARIN MARKET, BY PRODUCT, 2020-2028 ($MILLION)
TABLE 02.UNFRACTIONATED HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 03.LOW MOLECULAR WEIGHT HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 04.ULTRA-LOW MOLECULAR WEIGHT HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 05.HEPARIN MARKET, BY APPLICATION, 2020-2028 ($MILLION)
TABLE 06.VENOUS THROMBOEMBOLISM HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 07.CORONARY ARTERY DISEASE HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 08.ATRIAL FIBRILLATION HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 09.OTHERS HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 10.HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028 ($MILLION)
TABLE 11.HOSPITAL PHARMACIES HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 12.DRUG STORES AND RETAIL PHARMACIES HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 13.ONLINE PHARMACIES HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 14.HEPARIN MARKET, BY REGION, 2020-2028 ($MILLION)
TABLE 15.NORTH AMERICA HEPARIN MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 16.U.S. HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 17.U.S. HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 18.U.S. HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 19.CANADA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 20.CANADA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 21.CANADA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 22.MEXICO HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 23.MEXICO HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 24.MEXICO HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 25.NORTH AMERICA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 26.NORTH AMERICA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 27.NORTH AMERICA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 28.EUROPE HEPARIN MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 29.GERMANY HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 30.GERMANY HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 31.GERMANY HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 32.FRANCE HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 33.FRANCE HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 34.FRANCE HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 35.UK HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 36.UK HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 37.UK HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 38.ITALY HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 39.ITALY HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 40.ITALY HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 41.SPAIN HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 42.SPAIN HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 43.SPAIN HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 44.REST OF EUROPE HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 45.REST OF EUROPE HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 46.REST OF EUROPE HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 47.EUROPE HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 48.EUROPE HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 49.EUROPE HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 50.ASIA-PACIFIC HEPARIN MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 51.JAPAN HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 52.JAPAN HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 53.JAPAN HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 54.CHINA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 55.CHINA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 56.CHINA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 57.INDIA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 58.INDIA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 59.INDIA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 60.AUSTRALIA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 61.AUSTRALIA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 62.AUSTRALIA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 63.REST OF ASIA-PACIFIC HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 64.REST OF ASIA-PACIFIC HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 65.REST OF ASIA-PACIFIC HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 66.ASIA-PACIFIC HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 67.ASIA-PACIFIC HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 68.ASIA-PACIFIC HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 69.LAMEA HEPARIN MARKET, BY COUNTRY, 2020-2028 ($MILLION)
TABLE 70.BRAZIL HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 71.BRAZIL HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 72.BRAZIL HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 73.SOUTH AFRICA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 74.SOUTH AFRICA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 75.SOUTH AFRICA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 76.SAUDI ARABIA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 77.SAUDI ARABIA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 78.SAUDI ARABIA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 79.REST OF LAMEA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 80.REST OF LAMEA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 81.REST OF LAMEA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 82.LAMEA HEPARIN MARKET, BY PRODUCT, 2020-2028
TABLE 83.LAMEA HEPARIN MARKET, BY APPLICATION, 2020-2028
TABLE 84.LAMEA HEPARIN MARKET, BY DISTRIBUTION CHANNEL, 2020-2028
TABLE 85.BAXTER: COMPANY SNAPSHOT
TABLE 86.BAXTER: OPERATING SEGMENTS
TABLE 87.BAXTER: PRODUCT PORTFOLIO
TABLE 88.B. BRAUN: COMPANY SNAPSHOT
TABLE 89.B. BRAUN: OPERATING SEGMENTS
TABLE 90.B.BRAUN: PRODUCT PORTFOLIO
TABLE 91.DR. REDDY’S LAB: COMPANY SNAPSHOT
TABLE 92.DR. REDDY’S LAB: OPERATING SEGMENTS
TABLE 93.DR. REDDY’S LAB: PRODUCT PORTFOLIO
TABLE 94.FRESENIUS: COMPANY SNAPSHOT
TABLE 95.FRESENIUS: OPERATING SEGMENTS
TABLE 96.FRESENIUS: PRODUCT PORTFOLIO
TABLE 97.HEBEI: COMPANY SNAPSHOT
TABLE 98.FRESENIUS: OPERATING SEGMENTS
TABLE 99.HEBEI: PRODUCT PORTFOLIO
TABLE 100.LEO: COMPANY SNAPSHOT
TABLE 101.LEO: OPERATING SEGMENTS
TABLE 102.IBM: PRODUCT PORTFOLIO
TABLE 103.PFIZER: COMPANY SNAPSHOT
TABLE 104.PFIZER: OPERATING SEGMENTS
TABLE 105.PFIZER: PRODUCT PORTFOLIO
TABLE 106.SANOFI: COMPANY SNAPSHOT
TABLE 107.SANOFI: OPERATING SEGMENTS
TABLE 108.SANOFI: PRODUCT PORTFOLIO
TABLE 109.ASPEN: COMPANY SNAPSHOT
TABLE 110.TEVA: PRODUCT PORTFOLIO
TABLE 111.VIATRIS: COMPANY SNAPSHOT
TABLE 112.VIATRIS: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01.GLOBAL HEPARIN MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2020
FIGURE 01.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 02.MODERATE BARGAINING POWER OF BUYERS
FIGURE 03.HIGH THREAT OF SUBSTITUTES
FIGURE 04.MODERATE THREAT OF NEW ENTRANTS
FIGURE 05.MODERATE INTENSITY OF RIVALRY
FIGURE 06.TOP PLAYER POSITIONING, 2020
FIGURE 07.IMPACT ANALYSIS
FIGURE 08.COMPARATIVE ANALYSIS OF UNFRACTIONATED HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 09.COMPARATIVE ANALYSIS OF LOW MOLECULAR WEIGHT HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 10.COMPARATIVE ANALYSIS OF ULTRA-LOW MOLECULAR WEIGHT HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 11.COMPARATIVE ANALYSIS OF VENOUS THROMBOEMBOLISM HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF CORONARY ARTERY DISEASE HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 13.COMPARATIVE ANALYSIS OF ATRIAL FIBRILLATION HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF OTHERS HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF HOSPITAL PHARMACIES HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF ONLINE PHARMACIES HEPARIN MARKET, BY COUNTRY, 2020 & 2028 ($MILLION)
FIGURE 18.BAXTER: REVENUE, 2018–2020 ($MILLION)
FIGURE 19.BAXTER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 20.BAXTER: REVENUE SHARE BY REGION 2020 (%)
FIGURE 21.B BRAUN: NET SALES, 2018–2020 ($MILLION)
FIGURE 22.B BRAUN: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 23.B BRAUN: REVENUE SHARE BY REGION, 2020(%)
FIGURE 24.DR. REDDY’S LAB: REVENUE, 2018–2020 ($MILLION)
FIGURE 25.DR. REDDY’S LAB: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 26.DR. REDDY’S LAB: REVENUE SHARE BY REGION 2020 (%)
FIGURE 27.FRESENIUS: REVENUE, 2018–2020 ($MILLION)
FIGURE 28.FRESENIUS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 29.FRESENIUS: REVENUE SHARE BY REGION 2020 (%)
FIGURE 30.LEO: REVENUE, 2018–2020 ($MILLION)
FIGURE 31.LEO: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 32.LEO: REVENUE SHARE BY REGION 2020 (%)
FIGURE 33.PFIZER: REVENUE, 2018–2020 ($MILLION)
FIGURE 34.PFIZER: REVENUE SHARE BY REGION 2020 (%)
FIGURE 35.SANOFI: REVENUE, 2018–2020 ($MILLION)
FIGURE 36.SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 37.SANOFI: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 38.TEVA.: REVENUE, 2018–2020 ($MILLION)
FIGURE 39.TEVA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 40.VIATRIS: REVENUE, 2018–2020 ($MILLION)
FIGURE 41.VIATRIS: REVENUE SHARE BY REGION, 2020 (%)

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ヘパリンの世界市場2021年-2028年:製品別(未分画ヘパリン、低分子量ヘパリン(LMWH)、超低分子量ヘパリン(ULMWH))、用途別、流通チャネル別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆